Nautilus Biotechnology Q1 net loss narrows as expenses fall

Nautilus Biotechnology

28/04/2026 13:08

Overview

US proteomics platform developer's Q1 net loss narrowed from prior year

Operating expenses for Q1 fell 14% on lower salaries and facilities costs

Company advanced commercialization with new early access program and sales leadership

Outlook

Company says it is progressing toward full commercial launch of Voyager platform

Nautilus aims to expand Early Access customer base ahead of commercial launch

Company expects continued platform validation and scientific publication efforts

Result Drivers

LOWER OPERATING COSTS - Q1 operating expenses fell due to reduced salaries, benefits, stock-based compensation, and facilities costs

EARLY ACCESS PROGRAM - Initiated Iterative Mapping Early Access Program, expanding access to Tau proteoform assay and supporting platform validation

SALES LEADERSHIP - Appointed new VP of Global Sales to drive Early Access customer expansion and Voyager Platform adoption

Company press release: ID:nGNX24MJS1

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.12
Q1 Net Income
-$14.70 mln
Q1 Operating Expenses
$16.12 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Nautilus Biotechnology Inc is $4.00, about 55.6% above its April 27 closing price of $2.57

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)